NCT03823118 2023-02-23
S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer
Taizhou Hospital
Phase 2 Completed
Taizhou Hospital
National Cancer Center, Korea
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS